1.	STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-03, NCT00858572
2.	A Phase 1/2 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-04, NCT00964873
3.	A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-05, NCT01039519
4.	Clinical and Translational Study of STA-9090 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 10-029, NCT01111838
5.	Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 10-145, NCT01273896
6.	STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: Other Protocol IDs: 10-333, NCT01368003
7.	Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors Phase: Phase I Type: Treatment Status: Closed Age: 25 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-02, NCT00687934